0.45
-0.0451(-9.02%)
Currency In USD
| Previous Close | 0.5 |
| Open | 0.41 |
| Day High | 0.46 |
| Day Low | 0.39 |
| 52-Week High | 2.42 |
| 52-Week Low | 0.27 |
| Volume | 2.87M |
| Average Volume | 6.29M |
| Market Cap | 7.29M |
| PE | -0.31 |
| EPS | -1.48 |
| Moving Average 50 Days | 0.41 |
| Moving Average 200 Days | 0.86 |
| Change | -0.05 |
If you invested $1000 in Indaptus Therapeutics, Inc. (INDP) since IPO date, it would be worth $1.04 as of June 24, 2025 at a share price of $0.5. Whereas If you bought $1000 worth of Indaptus Therapeutics, Inc. (INDP) shares 5 years ago, it would be worth $19.97 as of June 24, 2025 at a share price of $0.5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants
GlobeNewswire Inc.
Jun 13, 2025 12:00 PM GMT
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced the sale of approx
Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
GlobeNewswire Inc.
Jun 02, 2025 12:00 PM GMT
New trial arm to evaluate safety, dosing and preliminary anti-tumor activity of the combination therapy in advanced solid tumorsNEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology c
Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit
GlobeNewswire Inc.
May 08, 2025 12:00 PM GMT
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announces that its Founder and Chief Scientific